APR, the Korean owner of Medicube, reported Q3 2026 revenue of €526m (KRW 773bn), up 100.3% year-on-year. Operating profit reached €109m (KRW 161bn), up 68.9%, but margin fell to 20.8% from 24.6%. Net profit increased 47.6% to €75m (KRW 110bn).

Cosmetics/Beauty reached €464m (KRW 682bn), up 150.6%, and accounted for 88% of sales, compared with 70.6% a year earlier. APR says regional, channel and category expansion drove the record quarter, supported by steady-seller sales and new bestseller expansion. Beauty Devices reached €58m (KRW 85bn), down 17.9%, and accounted for 11% of sales. Global cumulative device sales surpassed 8m units, but quarterly revenue declined without major global events. Cosmetics/Beauty now leads growth and makes up a much larger share of the business.
Overseas revenue reached €492m (KRW 723bn), up 135%, and accounted for 94% of sales. North America represented 46% of sales and Europe 23%; together they reached 69%, from 47% a year earlier. Korea accounted for 6% of sales and Asia 15%, together 21% versus 47% in Q3 25; Others were 10%. APR attributes a €19m (KRW 28bn) reduction in Q3 operating profit and a 3.6 percentage-point margin impact to the stronger won, through FX losses on foreign-currency receivables and lower KRW-translated revenue. The release provides no numerical full-year guidance. Source: APR 3Q 2026 Earnings Release. Euro conversions use 1 KRW = €0,00068.
Subscribe to my newsletter for weekly insights on the beauty industry. Link in the comments.